Biogen Inc.

271.21+0.7700+0.28%Vol 242.59K1Y Perf -19.31%
Apr 16th, 2021 10:38 DELAYED
BID271.03 ASK271.31
Open270.61 Previous Close270.44
Pre-Market270.92 After-Market-
 0.48 0.18%  - -
Target Price
294.41 
Analyst Rating
Hold 2.68
Potential %
8.41 
Finscreener Ranking
★★★+     51.44
Insiders Trans % 3/6/12 mo.
100/-/- 
Value Ranking
★★★★     57.13
Insiders Value % 3/6/12 mo.
100/-3/-3 
Growth Ranking
★★★★+     65.16
Insiders Shares Cnt. % 3/6/12 mo.
100/14/14 
Income Ranking
 —    -
Market Cap41.32B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
34.09 
Earnings Date
22nd Apr 2021

Today's Price Range

270.59273.83

52W Range

223.25363.92

5 Year PE Ratio Range

7.1032.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.85%
1 Month
4.05%
3 Months
-1.96%
6 Months
-3.42%
1 Year
-19.31%
3 Years
2.79%
5 Years
0.72%
10 Years
225.99%

TickerPriceChg.Chg.%
BIIB271.210.77000.28
AAPL134.12-0.3800-0.28
GOOG2 291.78-4.8800-0.21
MSFT259.34-0.1600-0.06
XOM56.63-0.3500-0.61
WFC43.180.94002.23
JNJ160.840.45000.28
FB305.84-1.9800-0.64
GE13.49-0.0600-0.44
JPM153.791.62001.06
Financial StrengthValueIndustryS&P 500US Markets
1.30
1.80
0.42
0.73
23.70
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
85.80
39.20
42.70
38.10
26.42
RevenueValueIndustryS&P 500US Markets
9.91B
65.06
2.66
5.30
Earnings HistoryEstimateReportedSurprise %
Q04 20204.934.58-7.10
Q03 20208.068.849.68
Q02 20208.0310.2627.77
Q01 20207.749.1418.09
Q04 20198.018.344.12
Q03 20198.279.1710.88
Q02 20197.589.1520.71
Q01 20196.876.981.60
Earnings Per EndEstimateRevision %Trend
3/2021 QR5.04-18.71Negative
6/2021 QR4.73-22.84Negative
12/2021 FY18.56-25.64Negative
12/2022 FY20.25-19.67Negative
Next Report Date22nd Apr 2021
Estimated EPS Next Report5.07
Estimates Count29
EPS Growth Next 5 Years %10.50
Volume Overview
Volume242.59K
Shares Outstanding152.34M
Trades Count4.22K
Dollar Volume314.09M
Avg. Volume1.24M
Avg. Weekly Volume675.89K
Avg. Monthly Volume947.17K
Avg. Quarterly Volume1.20M

Biogen Inc. (NASDAQ: BIIB) stock closed at 270.44 per share at the end of the most recent trading day (a 1.75% change compared to the prior day closing price) with a volume of 986.47K shares and market capitalization of 41.32B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9100 people. Biogen Inc. CEO is Michel Vounatsos.

The one-year performance of Biogen Inc. stock is -19.31%, while year-to-date (YTD) performance is 10.45%. BIIB stock has a five-year performance of 0.72%. Its 52-week range is between 223.25 and 363.92, which gives BIIB stock a 52-week price range ratio of 34.09%

Biogen Inc. currently has a PE ratio of 10.80, a price-to-book (PB) ratio of 3.78, a price-to-sale (PS) ratio of 4.04, a price to cashflow ratio of 10.10, a PEG ratio of 2.32, a ROA of 14.74%, a ROC of 27.76% and a ROE of 31.72%. The company’s profit margin is 26.42%, its EBITDA margin is 42.70%, and its revenue ttm is $9.91 Billion , which makes it $65.06 revenue per share.

Of the last four earnings reports from Biogen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $5.07 for the next earnings report. Biogen Inc.’s next earnings report date is 22nd Apr 2021.

The consensus rating of Wall Street analysts for Biogen Inc. is Hold (2.68), with a target price of $294.41, which is +8.41% compared to the current price. The earnings rating for Biogen Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biogen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biogen Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.31, ATR14 : 8.65, CCI20 : -21.14, Chaikin Money Flow : -0.05, MACD : -1.14, Money Flow Index : 58.45, ROC : -2.04, RSI : 49.05, STOCH (14,3) : 41.21, STOCH RSI : 1.00, UO : 42.32, Williams %R : -58.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biogen Inc. in the last 12-months were: Alfred W. Sandrock (Option Excercise at a value of $0), Alfred W. Sandrock (Sold 3 000 shares of value $1 050 000 ), Alphonse Galdes (Option Excercise at a value of $0), Chirfi Guindo (Option Excercise at a value of $0), Ginger Gregory (Option Excercise at a value of $0), Jesus B. Mantas (Buy at a value of $239 766), Michel Vounatsos (Buy at a value of $748 047), Michel Vounatsos (Option Excercise at a value of $0), Robin C. Kramer (Option Excercise at a value of $0), Susan H. Alexander (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (33.33 %)
9 (37.50 %)
8 (34.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
11 (45.83 %)
10 (41.67 %)
12 (52.17 %)
Moderate Sell
1 (4.17 %)
1 (4.17 %)
1 (4.35 %)
Strong Sell
4 (16.67 %)
4 (16.67 %)
2 (8.70 %)
Summary RatingHold
2.68
Hold
2.60
Moderate Buy
2.49

Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

CEO: Michel Vounatsos

Telephone: +1 617 679-2000

Address: 225 Binney Street, Cambridge 02142, MA, US

Number of employees: 9 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

49%51%

Bearish Bullish

63%37%

News

Stocktwits